PMID- 10954025
OWN - NLM
STAT- MEDLINE
DCOM- 20000830
LR  - 20181130
IS  - 0026-0495 (Print)
IS  - 0026-0495 (Linking)
VI  - 49
IP  - 8
DP  - 2000 Aug
TI  - Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 
      diabetes: do statins have a specific effect on triglyceride metabolism?
PG  - 1049-54
AB  - There is little information about the effect of an alteration of low-density 
      lipoprotein (LDL) turnover on chylomicron and very-low-density lipoprotein (VLDL) 
      metabolism, yet chylomicron remnant particles are thought to be particularly 
      atherogenic. This study examined the effect of inhibition of cholesterol 
      synthesis on postprandial lipoproteins. Eight type 2 diabetic patients were 
      examined before treatment with the 3-hydroxy-3-methyl glutaryl coenzyme A 
      (HMGCoA) reductase inhibitor cerivastatin, after 4 weeks on active treatment, and 
      4 weeks after stopping treatment. On each occasion, blood was collected fasting 
      and at 2-hour intervals for up to 8 hours after a high-fat meal. Chylomicrons and 
      VLDLs were isolated by sequential ultracentrifugation. Compositional analysis was 
      performed including the measurement of apolipoprotein B48 (apo B48) and apo B100 
      using polyacrylamide gradient gel electrophoresis. During statin treatment, there 
      was a significant reduction in the postprandial chylomicron apo B48 area under 
      the curve (AUC) from 23 +/- 16 to 17 +/- 10 (P < .01) and apo B100 in the 
      chylomicron fraction from 166 +/- 148 to 70 +/- 70 (P < .05). Postprandial 
      cholesterol (362 +/- 193 to 74 +/- 39, P < .005), triglyceride (2,222 +/- 1,440 
      to 746 +/- 329), and phospholipid (518 +/- 267 to 205 +/- 94) also decreased (P < 
      .005). In the VLDL fraction, the postprandial cholesterol and triglyceride AUC 
      were significantly reduced by statin (316 +/- 228 to 171 +/- 78, P < .05, and 
      1,733 +/- 833 to 857 +/- 468, P < .02, respectively). Four weeks after cessation 
      of treatment, the chylomicron fraction triglyceride AUC had returned to the 
      pretreatment level, but postprandial chylomicron cholesterol and VLDL 
      cholesterol, triglyceride, and phospholipid were significantly lower than 
      baseline (P < .05). Plasma total cholesterol and LDL cholesterol were 
      significantly reduced with treatment (6.2 +/- 0.5 to 4.3 +/- 1.0 mmol/L, P < 
      .001, and 4.5 +/- 0.4 to 2.8 +/- 1.0 mmol/L, P < .01, respectively) and returned 
      to baseline following cessation of treatment. Fasting plasma triglycerides 
      decreased significantly on treatment (2.4 +/- 1.0 to 1.7 +/- 0.2 mmol/L, P < .05) 
      but remained significantly lower than baseline 4 weeks later (1.8 +/- 0.3 mmol/L, 
      P < .05). This study suggests major postprandial lipoprotein changes on statin 
      therapy which may account, in part, for the beneficial effects of statins in the 
      prevention of myocardial infarction.
FAU - Battula, S B
AU  - Battula SB
AD  - Department of Endocrinology and Diabetes, Adelaide/Mental Hospital, Dublin, 
      Ireland.
FAU - Fitzsimons, O
AU  - Fitzsimons O
FAU - Moreno, S
AU  - Moreno S
FAU - Owens, D
AU  - Owens D
FAU - Collins, P
AU  - Collins P
FAU - Johnson, A
AU  - Johnson A
FAU - Tomkin, G H
AU  - Tomkin GH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (Apolipoprotein B-100)
RN  - 0 (Apolipoprotein B-48)
RN  - 0 (Apolipoproteins B)
RN  - 0 (Chylomicrons)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Lipoproteins, VLDL)
RN  - 0 (Pyridines)
RN  - 0 (Triglycerides)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - AM91H2KS67 (cerivastatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Apolipoprotein B-100
MH  - Apolipoprotein B-48
MH  - Apolipoproteins B/*blood
MH  - Cholesterol/blood
MH  - Chylomicrons/blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology
MH  - Intestinal Mucosa/metabolism
MH  - Intestines/drug effects
MH  - Lipoproteins, LDL/blood
MH  - Lipoproteins, VLDL/blood
MH  - Liver/drug effects/metabolism
MH  - Male
MH  - Middle Aged
MH  - Postprandial Period
MH  - Pyridines/*pharmacology
MH  - Triglycerides/*blood
EDAT- 2000/08/23 11:00
MHDA- 2000/09/02 11:01
CRDT- 2000/08/23 11:00
PHST- 2000/08/23 11:00 [pubmed]
PHST- 2000/09/02 11:01 [medline]
PHST- 2000/08/23 11:00 [entrez]
AID - S0026-0495(00)91637-8 [pii]
AID - 10.1053/meta.2000.7744 [doi]
PST - ppublish
SO  - Metabolism. 2000 Aug;49(8):1049-54. doi: 10.1053/meta.2000.7744.